Company Overview and News

 
Higher costs squeeze UltraTech’s Q2 profit

9h freepressjournal.in
Mumbai: UltraTech Cement on Friday reported an 11.33 per cent decline in consolidated net profit to Rs 375.74 crore for the quarter ended September 30 over higher energy and logistics costs. The Aditya Birla Group firm had posted a net profit of Rs 423.76 crore in the July-September quarter a year ago, the company said. The company’s total income was Rs 8,371.69 crore during the quarter, up 19.52 per cent against Rs 7,003.
532532 JIPKY UCLQY UCLQF JPASSOCIAT 532538 ULTRACEMCO

 
UltraTech Cement profit falls 9.4 % in September

2018-10-19 thehindubusinessline
UltraTech Cement Ltd's quarterly profit dropped 9.4 per cent and missed market expectations, hurt by higher expenses, the company's statement showed on Friday.
UCLQY UCLQF 532538 ULTRACEMCO

 
Q2 results: UltraTech Cement standalone profit at Rs 391 crore

2018-10-19 livemint
Mumbai: UltraTech Cement Ltd’s quarterly profit dropped 9.4% and missed market expectations, hurt by higher expenses, the company’s statement showed on Friday.
UCLQY UCLQF 532538 ULTRACEMCO

 
UltraTech Cement Limited - Financial Result Updates

2018-10-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UCLQY UCLQF 532538 ULTRACEMCO

 
UltraTech Cement Limited - Investor Presentation

2018-10-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UCLQY UCLQF 532538 ULTRACEMCO

 
UltraTech Cement Limited - Updates

2018-10-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UCLQY UCLQF 532538 ULTRACEMCO

 
UltraTech Cement Limited - Outcome of Board Meeting

2018-10-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UCLQY UCLQF 532538 ULTRACEMCO

 
I-Sec, UltraTech, SBI Life results on Friday

2018-10-17 thehindubusinessline
About 10 companies will announce their quarterly results on Thursday and Friday. While the boards of Anant Raj, Poddar Pigments and Muthoot Capital Services will meet on Thursday to consider their results, firms such as Bhansali Engineering Polymers, ICICI Securities, Sadhana Nitrochem, SBI Life Insurance Company, UltraTech Cement and VTM will declare their numbers on Friday. Traders will closely monitor the results of SBI Life, UltraTech, and ICICI Securities.
515055 MUTHTFN 532538 UCLQF ULTRACEMCO PODARPIGQ 511766 500052 524570 ANANTRAJ UCLQY SADHNANIQ BEPL 506642

 
Birla White to distribute new tools to painters

2018-10-16 thehindubusinessline
Birla White, a unit of Ultratech Cement Ltd, has launched a programme to distribute new advanced tools to painters.
UCLQY UCLQF 532538 ULTRACEMCO

5
Stock market weekly wrap: Sensex, Nifty snap 5 straight weeks of losses; Q2 results may chart course ahead

2018-10-13 financialexpress
Snapping a five-week losing streak, Sensex and Nifty made a comeback — gaining up to 1.5% — despite bears ruling the domestic equity markets for three out of five trading sessions during the week amid huge volatility. A respite came in the form of easing crude oil prices, a recovery in the rupee from record lows and value buying in banking, oil marketing companies and auto stocks.
500325 RELIANCE 532538 532187 RIGD UCLQY HDFCBANK HEROMOTOCO 500570 TATAMOTORS RLNIY YESBANK INDUSINDBK KMBKY UCLQF 532648 YYBKY ULTRACEMCO 500182 HDB 500180 KOTAKBANK HRTQY 500247 TTM

 
UltraTech Cement Limited - Updates

2018-10-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UCLQY UCLQF 532538 ULTRACEMCO

 
UltraTech Cement Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-10-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UCLQY UCLQF 532538 ULTRACEMCO

 
NCLAT order stayed; SC asks cement cos to pay 10% of Rs 6,300-cr penalty

2018-10-06 financialexpress
The Supreme Court on Friday stayed the National Company Law Appellate Tribunal (NCLAT)’s order that had upheld the Competition Commission of India’s (CCI) verdict imposing Rs 6,300-crore penalty on 11 cement companies over alleged cartelisation and asked them to deposit 10% of the amount.
500260 500425 RMCTY AMBUY UCLQY RAMCOCEM UCLQF 532538 AMBUJACEM ULTRACEMCO

 
Cement cos get a breather as SC stays ₹6,300-cr CCI penalty

2018-10-05 thehindubusinessline
On July 25, the NCLAT dismissed the cement-makers’ plea on the CCI penalty, following which they moved the court - AFP
500260 RMCTY UCLQY RAMCOCEM UCLQF 532538 ULTRACEMCO

 
UltraTech Cement Limited - Updates

2018-10-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UCLQY UCLQF 532538 ULTRACEMCO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...